Abstract
Cell-based therapies for Parkinson's and Huntington's disease have provided mixed clinical outcomes and one of the reasons underlying this is the use of primary fetal tissue as the source of grafted cells. An alternate source of cells, such as stem cells, could overcome many of the issues associated with primary fetal tissue and would help bring forward cell replacement therapy as a reliable and effective treatment for these two neurodegenerative disorders. This review will discuss which stem cells are likely to go to clinic in the next generation of cells, based on trials for Parkinson's and Huntington's disease.
| Original language | English |
|---|---|
| Pages (from-to) | 297-307 |
| Number of pages | 11 |
| Journal | Neurodegenerative disease management |
| Volume | 4 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - 2014 |
| Externally published | Yes |
Free keywords
- Cell- and Tissue-Based Therapy
- Fetal Research
- Fibroblasts
- Humans
- Huntington Disease
- Neurodegenerative Diseases
- Pluripotent Stem Cells
- Stem Cell Transplantation
- Tissue Engineering
- Journal Article
- Research Support, Non-U.S. Gov't
- Review